Compare
Anixa Biosciences Inc vs Reviva Pharmaceuticals Holdings, Inc. vs Aditxt, Inc. vs Tempest Therapeutics, Inc.
| Latest fiscal year | Anixa Biosciences Inc ANIX | Reviva Pharmaceuticals Holdings, Inc. RVPH | Aditxt, Inc. ADTX | Tempest Therapeutics, Inc. TPST |
|---|---|---|---|---|
| Year ended | 2025-10-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $3.2K | n/a |
| Revenue growth (YoY) | n/a | n/a | -97.6% | n/a |
| Gross margin | n/a | n/a | 8.4% | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$10.93M | -$19.86M | -$43.10M | -$26.26M |
| EPS (Diluted) | -$0.34 | n/a | -$1153.83 | -$6.33 |
| Operating cash flow | -$7.17M | -$24.59M | -$25.69M | -$26.82M |
| Free cash flow | n/a | n/a | -$25.70M | -$26.82M |
| Cash & equivalents | $1.24M | $14.44M | n/a | $7.71M |
| Total assets | $16.08M | $15.92M | $16.52M | $16.93M |
| Total liabilities | $2.13M | $7.28M | $12.56M | $10.26M |
| Shareholders' equity | $15.16M | $8.65M | $5.61M | $6.67M |
| Return on year-end equity | -72.1% | -229.7% | -768.3% | -393.9% |
| Shares outstanding | 33.01M | 5.87M | 411.5K | 4.93M |
Revenue, most recent five fiscal years
| Fiscal year | Anixa Biosciences Inc | Reviva Pharmaceuticals Holdings, Inc. | Aditxt, Inc. | Tempest Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $210.0K Ended 2024-10-31 | n/a | $3.2K Ended 2025-12-31 | $295.0K Ended 2017-12-31 |
| 1 year earlier | $210.0K Ended 2023-10-31 | n/a | $134.0K Ended 2024-12-31 | $653.0K Ended 2016-12-31 |
| 2 years earlier | n/a | n/a | $645.2K Ended 2023-12-31 | $277.0K Ended 2015-12-31 |
| 3 years earlier | $512.0K Ended 2021-10-31 | n/a | $933.7K Ended 2022-12-31 | $0 Ended 2014-12-31 |
| 4 years earlier | n/a | n/a | $105.0K Ended 2021-12-31 | $0 Ended 2013-12-31 |